Kairos Pharma (NYSEAMERICAN:KAPA) Earns “Buy” Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $9.00 target price on the stock.

Kairos Pharma Price Performance

NYSEAMERICAN:KAPA opened at $1.01 on Thursday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00. The company has a fifty day moving average of $1.34.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.